Bausch Health's quarter disappoints, guidance beats. But uncertainty prevails over patent litigation

A resolution in Xifaxan litigation along with any further Bausch + Lomb spinoff timing, represent the two most important future catalysts.

Related Keywords

Canada ,Jim Cramer ,Salix Pharmaceuticals ,Jim Cramer Charitable ,Bausch Health ,Bausch Health Companies ,Wall Street ,Asia Pacific ,Charitable Trust ,Pharmaceuticals ,Bausch Health Companies Inc ,Earnings ,Breaking News Markets ,Markets ,Investment Strategy ,Club Earnings ,Bausch Lomb Corp ,Business News ,